Pharmacological Activation of Mitochondrial Biogenesis for the Treatment of Various Pathologies

Whitney S. Gibbs, Natalie E. Scholpa, Craig C. Beeson, Rick G. Schnellmann

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations


Mitochondrial dysfunction is a key pathophysiological mediator in a variety of disease states, including cardiovascular disease, metabolic syndrome, neurodegeneration, and acute organ injury. Pharmacological activation of mitochondrial biogenesis enhances mitochondrial content and oxidative metabolism and improves organ function in conditions involving mitochondrial dysfunction. Due to the complexity of signaling cascades and transcriptional complexes that promote the assembly and function of mitochondria, identification of specific activators of mitochondrial biogenesis is limited. This chapter provides rationale for mitochondrial biogenesis as a therapeutic strategy, discusses the role of mitochondrial dysfunction in acute and chronic disease, and outlines the current state of pharmacological activators of mitochondrial biogenesis and their effects on disease outcomes.

Original languageEnglish (US)
Title of host publicationMitochondrial Dysfunction Caused by Drugs and Environmental Toxicants
Number of pages24
ISBN (Electronic)9781119329725
ISBN (Print)9781119329701
StatePublished - Feb 21 2018


  • Disease outcomes
  • Mitochondrial homeostasis
  • Oxidative metabolism
  • Therapeutics

ASJC Scopus subject areas

  • Chemistry(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Pharmacological Activation of Mitochondrial Biogenesis for the Treatment of Various Pathologies'. Together they form a unique fingerprint.

Cite this